ALKS Q1 2021 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$251M+2.1% YoY

Gross Profit

$210M83.7% margin

Operating Income

-$16M-6.5% margin

Net Income

-$22M-8.9% margin

EPS (Diluted)

$-0.14

QoQ Revenue Growth

-10.2%

Cash Flow

Operating Cash Flow

-$45M

Free Cash Flow

-$53M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$1.9B

Total Liabilities

$827M

Stockholders' Equity

$1.1B

Cash & Equivalents

$205M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$251M	$246M	+2.1%
Gross Profit	$210M	$199M	+5.7%
Operating Income	-$16M	-$37M	+56.0%
Net Income	-$22M	-$39M	+42.0%

Revenue Segments

Product

$130M50%

Vivitrol

$75M29%

Aristada And Aristada Initio

$55M21%